Indian Firms Blame U.S. Price Hikes On Compliance Costs
This article was originally published in PharmAsia News
Executive Summary
Put simply, Indian generic firms’ take on why the prices of some of their products have surged in the United States is down to strict inspections and the costs of compliance. Dr Reddy's Laboratories has clarified that it doesn't even market one of the products in question.